Evidence map›Paper›PMID 30770779›Full record

ArticleCell death & disease2019

MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway.

Tingting Wang, Gang Chen, Xuemei Ma, Yao Yang, Yali Chen, Yihan Peng, Zhigang Bai, Zhongtao Zhang, Huadong Pei, Wei Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. miRNAs in pancreatic cancer progression and metastasis.Clinical & experimental metastasis · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. MiRNA-mediated EMT and CSCs in cancer chemoresistance.Experimental hematology & oncology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Tingting WangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China.
Gang ChenDepartment of Integrated Traditional Chinese Medicine and Western Medicine, Tongji Hospital, Huazhong University of Science and Technology, 430030, Wuhan, China.
Xuemei MaDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China.
Yao YangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China.
Yali ChenState Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, 102206, Beijing, China.
Yihan PengState Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, 102206, Beijing, China.
Zhigang BaiDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China.
Zhongtao ZhangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China.
Huadong PeiGeorge Washington University Cancer Center, USA; Department of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Science, 2300 Eye Street, N.W, Washington, DC, 20037, USA. huadongpei@gwu.edu.
Wei GuoDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, 100050, Beijing, China. guoweibfh@163.com.
National Clinical Research Center for Digestive Diseases · CNBeijing Proteome Research Center · CNBeijing Friendship Hospital · CNCapital Medical University · CNGeorge Washington University · USHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite gemcitabine being the leading chemotherapeutic drug for pancreatic cancer, many patients still relapse due to the drug resistance. We previously reported the molecular link between FKBP51 mediated AKT inhibition and gemcitabine response in pancreatic cancers. However, the upstream regulator of this pathway, especially the involvement of non-coding RNAs in gemcitabine response is still not clear. Here we delineated the miRNA expression profile and key signaling pathways associated with gemcitabine response. Furthermore, we confirmed that miR-30a, one node of this network, regulated cellular response to gemcitabine through SNAI1-IRS1-AKT pathway. MiR-30a directly targeted SNAI1, which activates AKT and ERK through regulating IRS1 in vitro and in vivo. Clinically, miR-30a is downregulated in pancreatic cancer tissue and associated with overall patient survival. We also identified miR-30a as an AKT-FOXO3a-regulated gene that forms a feedback loop. Together, these results demonstrate that miR-30a is an upstream regulator of the Akt pathway with a critical role in cancer etiology and chemoresistance.

Indexed as

AgedAnimalsCell Line, TumorCell ProliferationCell SurvivalDeoxycytidineFemaleGemcitabineHumansInsulin Receptor Substrate ProteinsMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsMiddle AgedDeoxycytidineGemcitabineInsulin Receptor Substrate ProteinsIRS1 protein, humanMicroRNAsMIRN30b microRNA, humanProto-Oncogene Proteins c-aktSNAI1 protein, humanSnail Family Transcription Factors

Identifiers

PMID30770779
PMCPMC6377638
OpenAlexW2913233773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.